PROMINENT-DUKE
PROMINENT-DUKE
批准号:
10845753
负责人:
CHRISTOPHER M COUNTER
金额:
$23.83万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-06-22 至 2024-05-31
关键词:
AddressAgingAlcohol consumptionArchitectureBioinformaticsBiologicalBiological ModelsBody Weight decreasedBreastCRISPR screenCancer EtiologyCancer ModelCellsClonal EvolutionClustered Regularly Interspaced Short Palindromic RepeatsCollectionColorectalCommunitiesCountryDNADataData SetDevelopmentEndogenous FactorsEndometrialEnvironmentEnvironmental Risk FactorEpidemiologyEpigenetic ProcessEpithelial CellsEventExcisionExposure toGene ExpressionGenerationsGeneticGenomicsGoalsHigh-Risk CancerHumanIndividualInflammationInterventionIntervention StudiesInvestigationLife StyleLimited StageLinkMachine LearningMalignant - descriptorMalignant NeoplasmsMapsMeasuresMethodsModelingMolecularMolecular TargetMusMutateMutationNeoplasmsNormal CellNormal tissue morphologyObesityOrganoidsPathway AnalysisPathway interactionsPatternPhenotypePopulationPrevalenceProcessProteomeProteomicsResearch PersonnelRiskRisk FactorsRoleRouteSamplingStructure of parenchyma of lungTestingTimeTissue DonorsTissue SampleTissue imagingTissuesTumor PromotersTumor PromotionTumor TissueTumor stageUnhealthy Dietanticancer researchcancer preventioncancer riskcarcinogenesiscellular targetingchemical propertychemotherapydata integrationdetection methoddriver mutationenvironmental agentepidemiology studyepigenomicsexperiencegenome-widehematopoietic tissuehuman tissueimmune cell infiltratein vivo Modelinhibitorinnovationlifestyle factorsmouse modelmultidisciplinaryneoplasticnovelpromoterresponsesmall moleculesmoking cessationstemstem cellstooltranscriptomicstumortumorigenesiswhole genome
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The cancer research community is on the verge of a major leap in our understanding of the factors that contribute to human cancer risk. While it is clear that mutations in DNA, either spontaneous or environmentally induced, are essential for cancer development, recent advances have highlighted the importance of non-mutagenic factors as rate-limiting determinants of cancer risk in human populations and in mouse cancer models.
The root causes of human cancer have been widely debated, but most of the emphasis has been on the origins of the “driver” mutations that are ubiquitous in human tumours. Although epidemiology studies have highlighted the possible roles of lifestyle factors such as obesity, alcohol consumption, inflammation and poor diet in cancer risk, it has generally been assumed that these factors act directly or indirectly to cause mutations in DNA, thus contributing to tumour mutational burden and resulting in increased cancer risk. In contrast, recent sequencing studies have uncovered abundant mutations in normal human tissues, suggesting that even strong cancer driver mutations are not sufficient for cancer formation. These results were presaged by studies of mouse tumour models, some carried out more than 50 years ago, showing that promotion is the rate-limiting step in tumour development.
To identify the mechanisms that control mutated normal cells, and to elucidate the precise mechanisms by which promoting factors stimulate the conversion of these cells to neoplastic growth, we have assembled a multidisciplinary team of investigators with wide-ranging experience in epidemiology, genetics, computational network analysis and machine learning, tissue imaging of gene expression, single cell transcriptomics, and genome-wide CRISPR functional screens. We will focus human analysis on a unique collection of several thousand human normal and matched tumour samples from >20 countries, including regions of both high and low cancer risk. Detailed risk factor information and whole genome sequence data is available from all these samples as part of the Grand Challenge Mutographs study. Analysis of these samples, together with detailed intervention studies in human populations, mouse models and human organoids, will allow us to develop a roadmap of tumour promotion from single normal cells carrying driver mutations, through to malignant progression. Our findings will facilitate identification of the causative environmental factors that promote cancer and provide routes to new methods and approaches to cancer prevention based on a deeper understanding of the process of initiated cell selection by tumour promoting agents.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Proteasomal recruiters of PAX3-FOXO1 Designed via Sequence-Based Generative Models
-
批准号:10826068
-
项目类别:
-
资助金额:$15.77万
-
财政年份:2023
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Screening for Cys-Reactive Ligands to Target PAX3-FOXO1
-
批准号:10611002
-
项目类别:
-
资助金额:$36.94万
-
财政年份:2022
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo
-
批准号:10415753
-
项目类别:
-
资助金额:$49.82万
-
财政年份:2022
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
PROMINENT-DUKE
-
批准号:10625044
-
项目类别:
-
资助金额:$22.86万
-
财政年份:2022
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Genetic dissection of oncogenic RAS-driven tumor initiation in vivo
-
批准号:10610444
-
项目类别:
-
资助金额:$46.84万
-
财政年份:2022
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma
-
批准号:10221086
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2020
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Defining and targeting the molecular vulnerabilities of the PAX3-FOXO1 protein in rhabdomyosarcoma
-
批准号:10221081
-
项目类别:
-
资助金额:$3.81万
-
财政年份:2020
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Project 4: The role of codon bias in RAS tumorigenesis
-
批准号:9074410
-
项目类别:
-
资助金额:$68.71万
-
财政年份:2016
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
The role of dietary copper in melanoma
-
批准号:9767706
-
项目类别:
-
资助金额:$35.28万
-
财政年份:2015
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
The role of dietary copper in melanoma
-
批准号:8964773
-
项目类别:
-
资助金额:$36.37万
-
财政年份:2015
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
The effect of oncogenic Ras signaling strength on cancer
-
批准号:8827266
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2013
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
The effect of oncogenic Ras signaling strength on cancer
-
批准号:8505048
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2013
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Reducing dietary copper for the treatment of BRaf mutation-positive melanoma
-
批准号:8688182
-
项目类别:
-
资助金额:$19.87万
-
财政年份:2013
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Reducing dietary copper for the treatment of BRaf mutation-positive melanoma
-
批准号:8548773
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2013
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
The effect of oncogenic Ras signaling strength on cancer
-
批准号:9033078
-
项目类别:
-
资助金额:$20.05万
-
财政年份:2013
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Evaluating the impact of KRas codon bias on pancreatic cancer
-
批准号:8262516
-
项目类别:
-
资助金额:$7.85万
-
财政年份:2012
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Evaluating the impact of KRas codon bias on pancreatic cancer
-
批准号:8450777
-
项目类别:
-
资助金额:$7.38万
-
财政年份:2012
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Small molecular weight eNOS inhibitors for the treatment of pancreatic cancer
-
批准号:8076980
-
项目类别:
-
资助金额:$17.07万
-
财政年份:2011
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Small molecular weight eNOS inhibitors for the treatment of pancreatic cancer
-
批准号:8243520
-
项目类别:
-
资助金额:$20.49万
-
财政年份:2011
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
Cancer Biology
-
批准号:8180879
-
项目类别:
-
资助金额:$3.11万
-
财政年份:2010
-
负责人:CHRISTOPHER M COUNTER
-
依托单位:
海外基金